RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
Not yet recruiting · NCT06492317 · Registry updated 2024-07-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer | HER2-positive Gastric Cancer | Not yet recruiting | Phase 2 | 2024-07-09 | NCT06492317 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The First Affiliated Hospital of Zhengzhou University | 203 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou | China | 125 |